China’s drugs offer lifeline for global pharma as it peers over the patent cliff
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food…
-
Podcast: The FDA’s emerging aversion to advisory committees
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George…
-
Disruption due for long-held assumptions in biopharma, says BIA chair
Foundational certainties of the biopharma industry may no longer hold true for the sector’s future as paradigm shifts reshape the…
-
NewCo licensing models are tipping deals in favour of China’s biotechs
As pharma companies continue to license candidates developed in China, experts say a particular licensing model is allowing the country's…
-
VPAG stalemate threatens to exclude innovative medicines from the UK
Stalled negotiations around the UK's Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) between the UK government and…
-
Targeting energy expenditure: the next wave of obesity drugs
In the wake of their seismic ascension over the lucrative weight loss market, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are facing…
-
EU’s Pharma Package falls short of Europe’s goal of global competitiveness
In a bid to chase competitiveness, the EU is advancing its most drastic revision of pharmaceutical law in 20 years.…
-
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
Johnson & Johnson (J&J) has unveiled first-in-human data on its trispecific antibody that demonstrates a 100% response rate in a…
-
ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA
A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…